2022年5月6日金曜日

米FDAが実質的にJ&Jのワクチンにダメ出し

 FDA News Release

Coronavirus (COVID-19) Update: FDA Limits Use of Janssen COVID-19 Vaccine to Certain Individuals


For Immediate Release:

Today, the U.S. Food and Drug Administration has limited the authorized use of the Janssen COVID-19 Vaccine to individuals 18 years of age and older for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Janssen COVID-19 Vaccine because they would otherwise not receive a COVID-19 vaccine.

Key Points:

  • After conducting an updated analysis, evaluation and investigation of reported cases, the FDA has determined that the risk of thrombosis with thrombocytopenia syndrome (TTS), a syndrome of rare and potentially life-threatening blood clots in combination with low levels of blood platelets with onset of symptoms approximately one to two weeks following administration of the Janssen COVID-19 Vaccine, warrants limiting the authorized use of the vaccine.
  • The FDA has determined that the known and potential benefits of the vaccine for the prevention of COVID-19 outweigh the known and potential risks for individuals 18 years of age and older for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate, and for individuals 18 years of age and older who elect to receive the Janssen COVID-19 Vaccine because they would otherwise not receive a COVID-19 vaccine.
  • The Fact Sheet for Healthcare Providers Administering Vaccine  now reflects the revision of the authorized use of the Janssen COVID-19 Vaccine and includes a warning statement at the beginning of the fact sheet for prominence which summarizes information on the risk for TTS. Additionally, information on the revision to the authorized use of the vaccine and updated information on this risk of blood clots with low levels of blood platelets has been added to the Fact Sheet for Recipients and Caregivers

“We recognize that the Janssen COVID-19 Vaccine still has a role in the current pandemic response in the United States and across the global community. Our action reflects our updated analysis of the risk of TTS following administration of this vaccine and limits the use of the vaccine to certain individuals,” said Peter Marks, M.D., Ph.D., director of the FDA’s Center for Biologics Evaluation and Research. “Today’s action demonstrates the robustness of our safety surveillance systems and our commitment to ensuring that science and data guide our decisions. We’ve been closely monitoring the Janssen COVID-19 Vaccine and occurrence of TTS following its administration and have used updated information from our safety surveillance systems to revise the EUA. The agency will continue to monitor the safety of the Janssen COVID-19 Vaccine and all other vaccines, and as has been the case throughout the pandemic, will thoroughly evaluate new safety information.”

Background

The Janssen COVID-19 Vaccine was authorized for emergency use on Feb. 27, 2021. On April 13, 2021, the FDA and the Centers for Disease Control and Prevention (CDC), announced a recommended pause in administration of the vaccine to investigate six reported cases of TTS, and to help ensure that health care providers were made aware of the potential for TTS and could plan for proper recognition and management due to the unique treatment required for TTS.  
On April 23, 2021, following a thorough safety evaluation, including two meetings of the CDC’s Advisory Committee on Immunization Practices (ACIP), the FDA and CDC lifted the recommended pause regarding the use of the Janssen COVID-19 Vaccine. The agencies confirmed a total of 15 cases of TTS had been reported to the Vaccine Adverse Event Reporting System (VAERS), including the original six reported cases, out of approximately 8 million doses administered. 

These data, plus the deliberations and recommendations by the ACIP, helped with FDA’s assessment that the known and potential benefits of Janssen COVID-19 Vaccine outweighed its known and potential risks in individuals 18 years of age and older. The available data suggested the chance of TTS occurring was remote, but investigation into the level of potential excess risk due to vaccination and specific risk factors continued. At that time the Fact Sheet for Healthcare Providers Administering Vaccine was revised to include a warning pertaining to the risk of TTS and the Fact Sheet for Recipients and Caregivers was also revised to include information about blood clots in combination with low blood platelets after receiving the Janssen COVID-19 Vaccine. 

In December 2021, after reviewing updated vaccine effectiveness and safety data, the ACIP made a preferential recommendation for the use of mRNA COVID-19 vaccines over the Janssen COVID-19 Vaccine in all persons 18 years of age and older in the United States. The ACIP recommended and CDC endorsed that the Janssen COVID-19 Vaccine may be considered in some situations: when a person has a contraindication to receipt of mRNA COVID-19 vaccines, when a person would otherwise remain unvaccinated for COVID-19 due to limited access to mRNA COVID-19 vaccines, and when a person wants to receive the Janssen COVID-19 Vaccine despite the safety concerns identified.

Current Status

The FDA and CDC have continuously monitored for and investigated all suspected cases of TTS reported to VAERS. In an updated analysis of TTS cases following administration of the Janssen COVID-19 Vaccine that were reported to VAERS through March 18, 2022, the FDA and CDC have identified 60 confirmed cases, including nine fatal cases. The FDA has determined that the reporting rate of TTS is 3.23 per million doses of vaccine administered and the reporting rate of TTS deaths is 0.48 per million doses of vaccine administered.

In making the determination to limit the authorized use of the Janssen COVID-19 Vaccine, the agency considered that reporting rates of TTS and TTS deaths following administration of the Janssen COVID-19 Vaccine are not appreciably lower than previously reported. Furthermore, the factors that put an individual at risk for TTS following administration of Janssen COVID-19 Vaccine remain unknown. The FDA also considered that individuals with TTS may rapidly deteriorate, despite prompt diagnosis and treatment, that TTS can lead to long-term and debilitating health consequences and that TTS has a high death rate. The agency also considered the availability of alternative authorized and approved COVID-19 vaccines which provide protection from COVID-19 and have not been shown to present a risk for TTS.

Examples of individuals who may still receive the Janssen COVID-19 Vaccine include: individuals who experienced an anaphylactic reaction after receipt of an mRNA COVID-19 vaccine, individuals who have personal concerns with receiving mRNA vaccines and would otherwise not receive a COVID-19 vaccine and individuals who would remain unvaccinated for COVID-19 due to limited access to mRNA COVID-19 vaccines.

Ongoing Safety Monitoring

The FDA has a robust safety surveillance system in place to monitor the safety of COVID-19 vaccines approved and authorized for emergency use. The FDA is monitoring COVID-19 vaccine safety through both passive and active safety surveillance systems in collaboration with the CDC, the Centers for Medicare and Medicaid Services, the Department of Veterans Affairs and other academic and large non-government healthcare data systems.

The revised EUA for the Janssen COVID-19 Vaccine was issued to Janssen Biotech Inc., a Janssen Pharmaceutical Company of Johnson & Johnson.

Related Information

###

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-limits-use-janssen-covid-19-vaccine-certain-individuals


まあ要するに接種するならファイザーかモデルナにしろって話ですな。

要するにダメ出し。

何とかもっとワクチン・ブースターを打たせようとの必死の思いが伝わってきますねえ・・・(爆wwwwwwwwwww

5 件のコメント:

匿名 さんのコメント...

https://www.mhlw.go.jp › co...PDF
1 事 務 連 絡 令和4年4月28日 都道府県 各 市 町 村 衛生主管部(局) 御中 特 別 区 - 厚生労働省
2022/04/28 —
...3.ワクチンの種類及び供給について
4回目接種で使用するワクチンについては、分科会において、薬事上の承認を受けているファイザー社ワクチン及び武田/モデルナ社ワクチンを使用することが適当であるとされた。なお、接種の用量等については、3回目接種と同様とすることが適当であるとされた。
ワクチンの供給について、3回目接種と同様に、国から都道府県別の配分量や配送スケジュール等を示す予定であり、詳細は追って連絡する。また、実際の割り当て作業はV-SYSを活用する予定である。
なお、3回目接種用に配送したファイザー社ワクチン及び武田/モデルナ社ワクチンは、4回目接種にも使用することができる。有効期限の短いバイアルから3回目接種や4回目接種に使用する等、ワクチンを有効に活用すること。

匿名 さんのコメント...

NHK
ノババックス社のコロナワクチン承認 効果や副反応、活用は?
新型コロナウイルスのワクチンで、ファイザーやモデルナとは仕組みが異なるアメリカの製薬会社ノババックスが開発したワクチンについて、厚生労働省...
2週間前

朝日新聞デジタル
ノババックス製ワクチン、3回目接種の効果は? 海外での使用 ...
米ノババックス社製の新型コロナウイルスワクチンは、5月下旬にも全国で接種が始まる見通しです。既存のワクチンと異なる「組み換えたんぱく」の...
1週間前

京都新聞
米ノババックス製、作り方異なる新ワクチン 交互接種の効果は【Q&A】
国内4種類目の新型コロナウイルスワクチンとして、米企業ノババックス製が4月に承認されました。 Q どんなワクチン? A 既にあるワクチン製…
3日前

Yahoo!ニュース
ノババックス製コロナワクチンの特徴は? ファイザー ...
ノババックス社製ワクチンの主成分は、新型コロナウイルスがヒトの細胞に感染する際にまず結合する、ウイルス表面にある突起状の「スパイク(S)...
1週間前

NHK.JP
ノババックスのワクチンが正式承認 早ければ来月末接種開始へ
アメリカの製薬会社ノババックスが開発した新型コロナウイルスワクチンについて、厚生労働省は19日に18歳以上を対象に使用することを正式に承認しま...
2週間前

東京新聞
1億5000万回分需要ある?国内4種目のノババックス製ワクチン 全未接種者に使用しても使い残す恐れ
国内で使える4種類目の新型コロナウイルスワクチンとして、米ノババックス製が厚生労働省に承認された。だが、国民の約半分が3回目接種を済ませ、3...
2週間前

読売新聞オンライン
米ノババックス製ワクチン、厚労省部会が「製造販売の承認」了承…5月下旬にも全国配送
厚生労働省の専門家部会は18日、米ノババックスが開発した新型コロナウイルスワクチンの製造販売の承認を了承した。現在主流の米ファイザー製、米...
2週間前

毎日新聞
ノババックス社のワクチン接種了承 日本国内で使用可能は4種類に - 毎日新聞
厚生労働省の予防接種・ワクチン分科会は27日、米ノババックス社が開発した新型コロナウイルスワクチンについて、1~3回目で使えることを了承した。
1週間前

匿名 さんのコメント...

消費期限の迫るワクチンの有効活用

匿名 さんのコメント...

> J&Jのワクチンにダメ出し

Jew & Japanにもダメ出されてそうwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwwww><

匿名 さんのコメント...

https://kr.usembassy.gov › 081421-...
U.S. sends 400,000 Janssen doses to ROK; to arrive Sunday - U.S. Embassy & Consulate in the Republic of Korea
2021/08/14 — The United States will provide our close ally and partner the Republic of Korea with 400,000 doses of the Johnson & Johnson (Janssen) COVID-19 ...

コメントを投稿